Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small …
WEBJun 25, 2024 · Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Adjuvant durvalumab extends survival in small cell lung cancer
WEB1 day ago · Participants were randomly allocated to receive durvalumab 1,500 mg (264 patients), durvalumab 1,500 mg plus tremelimumab 75 mg (four doses only; 200 patients), or placebo (266 patients) every ...
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
WEBJun 25, 2024 · The immunotherapy drug durvalumab (Imfinzi) helped people with early-stage small cell lung cancer live longer, according to initial results from a large clinical trial. Durvalumab is a type of immunotherapy called an immune checkpoint inhibitor.
Durvalumab Consolidation Therapy Extends Survival in Limited …
WEBJun 25, 2024 · Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial presented at the 2024 ASCO Annual Meeting by David ...
Imfinzi is first and only immunotherapy to show survival benefit in ...
WEBJun 2, 2024 · Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Interim ADRIATIC Results: Durvalumab Improves ... - ASCO Daily News
WEBJun 2, 2024 · Interim results from the long-awaited ADRIATIC trial found consolidation treatment with the selective monoclonal antibody durvalumab is associated with statistically significant and clinically meaningful improvements in survival versus placebo among patients with limited-stage small cell lung cancer (LS-SCLC; LBA5).
Overall Survival with Durvalumab after Chemoradiotherapy in …
WEBSep 25, 2018 · An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable...
Perioperative Durvalumab for Resectable Non–Small-Cell Lung …
WEBOct 23, 2023 · Durvalumab is a selective, high-affinity, human IgG1 monoclonal antibody that inhibits interaction of PD-L1 with PD-1 and CD80 by binding to PD-L1. 28 Findings from the PACIFIC trial have...
Consolidation Therapy With Durvalumab for Limited-Stage SCLC
WEBJun 2, 2024 · Results from an interim analysis of the phase III ADRIATIC study demonstrated that consolidation therapy after chemoradiotherapy with durvalumab extends survival in patients with limited-stage small-cell lung cancer (SCLC) compared to the current standard-of-care treatment of chemoradiotherapy alone.
Durvalumab Significantly Improves Survival for Patients With …
WEBResults from the randomized international phase III TOPAZ-1 trial showed that the checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs.
Skip to content